Avellino
Sarvari Panchumarthi is currently the Head of Research & Development at Avellino. Previously, Sarvari held positions in various scientific and research roles at companies such as Stanford University School of Medicine, Invitae, Ambry Genetics, and more. With a strong background in Molecular and Cellular Biology, Neurobiology, and Genetics, Sarvari has extensive experience in clinical genomics, rare diseases, natural history studies, and personalized medicine. Sarvari has also worked on various research projects and clinical trials, demonstrating their expertise in advancing the field of genetics. Additionally, Sarvari has a proven track record of managing teams, developing study protocols, and collaborating with various stakeholders to achieve research goals.
Avellino
Avellino turns genomic analytics into actionable healthcare insights, creating a healthier future for all. Powered by artificial intelligence and machine learning, its genetic discovery engine drives disruptive healthcare innovations. Avellino’s expertise spans a broad spectrum of healthcare specialties, including the impact of genetics in ophthalmology, oncology, pathogenomics and infectious diseases. As a global leader in leveraging artificial intelligence-powered algorithms, Avellino’s diagnostics provide eye care professionals with personalized genetic data to predict eye disease, prevent disease progression and ultimately preserve vision. Avellino has completed more than one million genetic eye tests since 2008, commercialized in the United States, South Korea and Japan. Its world class CLIA-certified laboratory in California has tested more than four million patients for COVID and RSV. Avellino’s research and development team has made groundbreaking discoveries leveraging genetic data, with programs in early detection of oncology, a polygenic risk analysis for glaucoma, and a siRNA gene-silencing therapeutic for the treatment of granular corneal dystrophy type II (currently in preclinical development). With a focus on health equity, Avellino prioritizes the inclusion of ethnically diverse populations in its studies to maximize the impact of its genomics breakthroughs for global healthcare. Avellino is headquartered in Silicon Valley, California, with operations in Korea, Japan, and the UK.